Avid Bioservices Inc (CDMO)

[entdoc]

dia and bioBS, the results of Bavituximab and Sorafenib vs. liver cancer will in all likelihood not be a knockout, but a scorecard decision based on statistical significance. If statistically significant improvement is noted in the required metrics it will establish that, indeed, Bavituximab has anti-cancer effects, something we know already, and it would (hopefully) ratchet up the urgency of adding Bavi to early stage cancer treatment strategies...and to add Bavi to irradiation protocols. It is possible in some situations, depending on trial design, to show statistical significance which does not dictate future use of a pharmaceutical because of cost:benefit ratio, etc. Our experience with Bavi to date does not presage a home-run, but then even pitchers know balls out of the park on unusual occasions.